In 2014, Damon Runyon scientists pioneered new, cutting-edge ways to diagnose and treat all forms of cancer.

Damon Runyon Scientists

- Are harnessing the immune system to attack and destroy cancers like melanoma, advanced leukemia, non-small cell lung cancer, and more.
- Led the largest-ever genomic analysis of lung adenocarcinoma, identifying key mutations that are potential targets for personalized cancer treatment.
- Developed a new handheld scanner that can accurately detect brain tumor cells during surgery, enabling their removal.
- Created a new nanotechnology “cage” that can deliver small drug molecules deep into cancer cells.
- Developed a method to sequence the genomes of single breast cancer cells to understand tumor heterogeneity and its impact on clinical outcomes.

Awards and Honors

Elaine V. Fuchs, PhD, former Fellow and current Board Member, and former Clinical Investigator Jedd D. Wolchok, MD, PhD, received prestigious career achievement awards from the American Association for Cancer Research.

Former Fellow Pardis C. Sabeti, MD, PhD, received the Vilcek Prize for Creative Promise in Biomedical Science.

Dale F. Frey Breakthrough Scientist Adam de la Zerda, PhD, was named to the Forbes “30 Under 30” list in Science and Healthcare.

Innovator Feng Zhang, PhD, received the highest honor given by the National Science Foundation, the Alan T. Waterman Award.

Former Fellow Gordon J. Freeman, PhD, was one of the recipients of the William B. Coley Award for Distinguished Research in Tumor Immunology.

Innovator Emily P. Balskus, PhD, was listed in MIT Technology Review’s “35 Innovators under 35.”
To accelerate breakthroughs, the Damon Runyon Cancer Research Foundation provides today’s best young scientists with funding to pursue innovative cancer research.

152 scientists are currently being funded at 57 leading institutions in 17 states.

$17 million of new awards were funded in 2014.

Beginning this year, Damon Runyon is increasing its research funding by 33%.

100% of donations fund cancer research.

Our low administrative costs are paid from Damon Runyon Broadway Tickets and our endowment.

Operating Revenue: $21 million
- Donations and income: 47.6%
- Draw from endowment: 52.4%

Expenses: $21 million
- Programs: 87.8%
- Administration: 12.2%

www.damonrunyon.org 1.877.7CANCER